Merus N.V. (MRUS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Utrecht, Netherlands. El CEO actual es Jan van de Winkel.
MRUS tiene fecha de IPO 2016-05-19, 260 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $6.83B.
Merus N.V. is a clinical-stage immuno-oncology company headquartered in Utrecht, the Netherlands, focused on discovering and developing bispecific antibody therapeutics. The company's pipeline includes several candidates in various development stages, notably Zenocutuzumab (MCLA-128) in Phase 2 trials for metastatic breast cancer, along with MCLA-158, MCLA-145, MCLA-129, and ONO-4685 in Phase 1 or Phase 1/2 trials for various solid tumors and hematologic malignancies. Merus has established strategic collaborations with Betta Pharmaceuticals and Incyte Corporation to advance select candidates in its portfolio. Founded in 2003, the company leverages its bispecific antibody platform to develop novel cancer therapeutics targeting multiple pathways simultaneously.
